Impact of the SIK3 pathway inhibition on osteoclast differentiation via oxidative phosphorylation
- PMID: 39030684
- DOI: 10.1093/jbmr/zjae105
Impact of the SIK3 pathway inhibition on osteoclast differentiation via oxidative phosphorylation
Abstract
Maintenance of bone homeostasis and the balance between bone resorption and formation are crucial for maintaining skeletal integrity. This study sought to investigate the role of salt-inducible kinase 3 (SIK3), a key regulator in cellular energy metabolism, during the differentiation of osteoclasts. Despite osteoclasts being high energy-consuming cells essential for breaking down mineralized bone tissue, the specific function of SIK3 in this process remains unclear. To address this issue, we generated osteoclast-specific SIK3 conditional knockout mice and assessed the impact of SIK3 deletion on bone homeostasis. Our findings revealed that SIK3 conditional knockout mice exhibited increased bone mass and an osteopetrosis phenotype, suggesting a pivotal role for SIK3 in bone resorption. Moreover, we assessed the impact of pterosin B, a SIK3 inhibitor, on osteoclast differentiation. The treatment with pterosin B inhibited osteoclast differentiation, reduced the numbers of multinucleated osteoclasts, and suppressed resorption activity in vitro. Gene expression analysis demonstrated that SIK3 deletion and pterosin B treatment influence a common set of genes involved in osteoclast differentiation and bone resorption. Furthermore, pterosin B treatment altered intracellular metabolism, particularly affecting key metabolic pathways, such as the tricarboxylic acid cycle and oxidative phosphorylation. These results provide valuable insights into the involvement of SIK3 in osteoclast differentiation and the molecular mechanisms underlying osteoclast function and bone diseases.
Keywords: mitochondria; mitochondrial respiration; osteoclasts; oxidative phosphorylation; salt-inducible kinase 3.
Plain language summary
Osteoporosis is a disease that causes bones to become weak and fragile, increasing the risk of fractures especially in elderly. It is caused by an imbalance between the formation of new bone and the destruction of old bone. Cells called osteoclasts are responsible for breaking down old bone. Excessive osteoclast activity results in bone loss and osteoporosis. Our research has identified a LKB1-SIK3 pathway, which acts as an energy sensor in osteoclasts. We found that this pathway is activated when osteoclast activity is increased, and we were able to reduce osteoclast activity by genetically removing or inhibiting SIK3. These findings suggest that targeting the LKB1-SIK3 pathway may be a promising new approach for the treatment of osteoporosis. Developing drugs that inhibit SIK3 may slow bone loss and reduce the risk of fractures in osteoporotic patients.
© The Author(s) 2024. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.J Cell Biochem. 2020 Nov;121(11):4542-4557. doi: 10.1002/jcb.29677. Epub 2020 Feb 12. J Cell Biochem. 2020. PMID: 32048762
-
New mechanistic understanding of osteoclast differentiation and bone resorption mediated by P2X7 receptors and PI3K-Akt-GSK3β signaling.Cell Mol Biol Lett. 2024 Jul 8;29(1):100. doi: 10.1186/s11658-024-00614-5. Cell Mol Biol Lett. 2024. PMID: 38977961 Free PMC article.
-
The calcium channel TRPV6 is a novel regulator of RANKL-induced osteoclastic differentiation and bone absorption activity through the IGF-PI3K-AKT pathway.Cell Prolif. 2021 Jan;54(1):e12955. doi: 10.1111/cpr.12955. Epub 2020 Nov 7. Cell Prolif. 2021. PMID: 33159483 Free PMC article.
-
Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.Adv Drug Deliv Rev. 2005 May 25;57(7):959-71. doi: 10.1016/j.addr.2004.12.018. Epub 2005 Apr 15. Adv Drug Deliv Rev. 2005. PMID: 15876398 Review.
-
Novel Insights into Osteoclast Energy Metabolism.Curr Osteoporos Rep. 2023 Dec;21(6):660-669. doi: 10.1007/s11914-023-00825-3. Epub 2023 Oct 10. Curr Osteoporos Rep. 2023. PMID: 37816910 Free PMC article. Review.
Cited by
-
Deciphering Mitochondria: Unveiling Their Roles in Mechanosensing and Mechanotransduction.Research (Wash D C). 2025 Aug 8;8:0816. doi: 10.34133/research.0816. eCollection 2025. Research (Wash D C). 2025. PMID: 40785969 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials